Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

European Journal of Cancer

Volumn 84, Issue , 2017, Pages 88-101

  Rydzewska, Larysa H M ^a   Burdett, Sarah ^a   Vale, Claire L ^a   Clarke, Noel W ^b   Fizazi, Karim ^c   Kheoh, Thian ^d   Mason, Malcolm D ^e   Miladinovic, Branko ^d   James, Nicholas D ^f,g   Parmar, Mahesh K B ^a   Spears, Melissa R ^a   Sweeney, Christopher J ^h   Sydes, Matthew R ^a   Tran, NamPhuong ^d   Tierney, Jayne F ^a  

^a MRC CLINICAL TRIALS UNIT   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^g QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Abiraterone; Androgen deprivation therapy; Meta analysis; Metastases; Prostate cancer; Systematic review

Indexed keywords

ABIRATERONE ACETATE; ANTIANDROGEN; BICALUTAMIDE; DOCETAXEL; PREDNISOLONE; PREDNISONE; ABIRATERONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER GROWTH; CARDIOTOXICITY; COMBINATION DRUG THERAPY; DRUG EFFECT; GLEASON SCORE; HORMONE SENSITIVITY; HUMAN; LIVER TOXICITY; MALE; META ANALYSIS; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT OUTCOME; VASCULAR DISEASE; AGE; AGED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PATHOLOGY; PROSTATIC NEOPLASMS; RISK FACTOR; TIME FACTOR;

AGE FACTORS; AGED; ANDROGEN ANTAGONISTS; ANDROSTENES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHI-SQUARE DISTRIBUTION; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; PREDNISOLONE; PREDNISONE; PROSTATIC NEOPLASMS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85026815290     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.07.003     Document Type: Article

References (24)

1. Sharifi, N., Gulley, J.L., Dahut, W.L., Sharifi, N., Gulley, J.L., Dahut, W.L., An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer 17:4 (2010), R305–R315.
2. Labrie, F., Dupont, A., Belanger, A., Giguere, M., Lacoursiere, Y., Emond, J., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. J Steroid Biochem 23:5B (1985), 833–841.
3. Attard, G., Richards, J., de Bono, J.S., Attard, G., Richards, J., de Bono, J.S., New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clin Cancer Res 17:7 (2011), 1649–1657.
4. de Bono, J.S., Logothetis, C.J., Molina, A., Fizazi, K., North, S., Chu, L., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:21 (2011), 1995–2005.
5. Shiota, M., Eto, M., Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer. Int J Urol 23:5 (2016), 360–369.
6. Gillessen, S., Attard, G., Beer, T.M., Beltran, H., Bossi, A., Bristow, R., et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol, 2017:Jun 24, 10.1016/j.eururo.2017.06.002 pii: S0302–2838(17)30497-9. [Epub ahead of print].
7. Tierney, J.F., Vale, C.L., Burdett, S., Fisher, D., Rydzewska, L.H.M., Parmar, M.K.B., Timely and reliable evaluation of the effects of interventions: a framework for adaptive meta-analysis (FAME). Trials, 18(Suppl. 1), 2017, P351.
8. Rydzewska, L., Tierney, J., Burdett, S., Vale, C., Fisher, D., Mason, M., et al. Systematic review and meta-analysis of the effects of abiraterone for hormone-sensitive metastatic prostate cancer. PROSPERO 2017:CRD42017058300, 2017 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017058300.
9. Stewart, L.A., Clarke, M., Rovers, M., Riley, R.D., Simmonds, M., Stewart, G., et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. JAMA 313:16 (2015), 1657–1665.
10. Vale, C.L., Burdett, S., Rydzewska, L.H., Albiges, L., Clarke, N.W., Fisher, D., et al. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:2 (2016), 243–256.
11. Fizazi, K., Tran, N., Fein, L., Matsubara, N., Rodriquez-Antolin, A., Alekseev, B.Y., et al. Abiraterone plus prednisone in metastatic castration-sensitive prostate cancer. N Engl J Med, 2017, 10.1056/NEJMoa1704174 Epub June 4, 2017.
12. James, N.D., de Bono, J.S., Spears, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med, 2017, 10.1056/NEJMoa1702900 Epub June 3, 2017.
13. Yusuf, S., Peto, R., Lewis, J.A., Collins, R., Sleight, P., Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27 (1985), 335–371.
14. Deeks, J.J., Higgins, J.P.T., Altman, D.G., Chapter 9: analysing data and undertaking meta-analyses. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions version 5.1.0, 2011, The Cochrane Collaboration.
15. Higgins, J.P.T., Thompson, S.G., Quantifying heterogeneity in a meta-analysis. Stat Med 21 (2002), 1539–1558.
16. Fisher, D.J., Copas, A.J., Tierney, J.F., Parmar, M.K.B., A critical review of methods for the assessment of patient-level interactions in individual patient data (IPD) meta-analysis of randomised trials, and guidance for practitioners. J Clin Epidemiol 64 (2011), 949–967.
17. Fisher, D.J., Carpenter, J.R., Morris, T.P., Freeman, S.C., Tierney, J.F., Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?. BMJ, 356, 2017, j573.
18. Sydes, M.R., Parmar, M.K., Mason, M.D., Clarke, N.W., Amos, C., Anderson, J., et al. Flexible trial design in practice – stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials, 13, 2012, 168.
19. Davis, I.D., Stockley, M.R., Martin, A., Long, A., Yip, S., Coskinas, X., et al. Randomised phase 3 trial of enzalutamide in first line androgen deprivation for metastatic prostate cancer: ENZAMET (ANZUP 1304). Ann Oncol, 25(Suppl. 4), 2015 804TiP: iv278.
20. Stenzl, A., Krivoshik, B., Baron, B., Hirmand, M., Armstrong, A., Efficacy and safety of enzalutamide plus androgen deprivation therapy vs placebo plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: the ongoing ARCHES trial. Ann Oncol, 27(Suppl. 6), 2016 767TiP.
21. Smith, M., Saad, F., Hussain, M., Sternberg, C., Fizazi, K., Crawford, D., et al. A phase 3 randomized, double-blind, placebo-controlled trial of ODM-201 vs. placebo in combination with standard androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer (ARASENS). Eur Urol Suppl, 16(3), 2017, e356.
22. Lefebvre, C., Manheimer, E., Glanville, J., on behalf of the Cochrane Information Retrieval Methods Group. Searching for studies. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions, 2008, John Wiley & Sons Ltd, Chichester, 95–150.
23. Wong, S.S., Wilczynski, N.L., Haynes, R.B., Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 94:1 (2006), 41–47.
24. Wanling, Xie, Meredith, M. Regan, Marc, Buyse, Susan, Halabi, Philip, W. Kantoff, Oliver, Sartor, et al., on behalf of the ICECaP Working Group. Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer. J Clin Oncol, 2017 [in press].